BOULDER, Colo., May 12, 2026
Enliven Therapeutics announced new positive clinical findings from its ongoing Phase 1 ENABLE trial evaluating ELVN-001 in patients with chronic myeloid leukemia (CML), reinforcing the investigational therapy’s potential as a best-in-class targeted leukemia treatment. The data, selected for an oral presentation at the European Hematology Association (EHA) 2026 Congress, demonstrated encouraging efficacy and a favorable safety profile in heavily pretreated patients with relapsed or refractory CML.
The latest results further strengthen Enliven Therapeutics’ position in the competitive oncology market as pharmaceutical companies continue advancing precision medicines designed to overcome resistance to existing tyrosine kinase inhibitors (TKIs). ELVN-001 is a highly selective small molecule kinase inhibitor specifically engineered to target the BCR::ABL1 gene fusion, the primary oncogenic driver responsible for CML progression.
ELVN-001 Demonstrates Strong Molecular Responses
According to the company, patients treated with ELVN-001 achieved robust molecular responses despite receiving multiple prior therapies. In the mature 80 mg once-daily Phase 1b cohort, 47% of patients achieved major molecular response (MMR), while 38% reached MMR within 24 weeks of treatment.
Among patients previously treated with asciminib, a difficult-to-treat population with significant resistance to available therapies, ELVN-001 produced particularly encouraging results. The company reported a cumulative MMR rate of 52%, with 38% of evaluable patients achieving MMR by week 24.
Advertisement
In the randomized 60 mg and 120 mg cohorts, the therapy continued to demonstrate strong efficacy. Of 26 evaluable patients, 69% were in major molecular response, while more than half achieved MMR within 24 weeks. Researchers stated that these outcomes compared favorably to precedent Phase 1 clinical trial data for approved BCR::ABL1 tyrosine kinase inhibitors, particularly considering the heavily pretreated patient population enrolled in the ENABLE study.
The company also confirmed that all evaluable patients who entered the study already in major molecular response maintained or deepened their responses during treatment, highlighting the durability of ELVN-001’s anti-leukemic activity.
Favorable Safety Profile Supports Continued Development
Enliven Therapeutics emphasized that ELVN-001 maintained a favorable safety and tolerability profile across the study population. The ongoing Phase 1 trial enrolled 141 patients across multiple dose levels ranging from 10 mg to 160 mg once daily, with most patients remaining on treatment for a median duration of nearly 32 weeks.
Importantly, fewer than 10% of patients required dose reductions because of treatment-emergent adverse events, while only 6.4% discontinued therapy due to adverse effects. The company stated that the safety findings continue to align with ELVN-001’s highly selective kinase inhibition profile.
Researchers also noted that many patients enrolled in the study had extensive prior treatment histories. Approximately 67% of participants had received three or more prior unique TKIs, while nearly one-quarter had received five or more previous therapies before entering the trial.
Precision Oncology Strategy Gains Momentum
Enliven Therapeutics believes ELVN-001 could emerge as a differentiated therapy in the growing precision oncology landscape due to its selective mechanism and activity against mutations associated with drug resistance. The company stated that the investigational therapy was specifically designed to target resistance-associated mutations, including T315I, one of the most challenging mutations in CML treatment.
The oral presentation at EHA 2026 is expected to include updated clinical data with additional patient follow-up and longer treatment duration, potentially strengthening confidence in ELVN-001’s future regulatory and commercial prospects. As biotechnology companies continue developing next-generation targeted cancer therapies, Enliven Therapeutics is positioning ELVN-001 as a potentially important new treatment option for patients with resistant and relapsed chronic myeloid leukemia.
Source: Enliven Therapeutics press release
